scholarly journals Clinical Response of Convalescent Plasma Therapy in COVID-19 Patients in Dr. Saiful Anwar General Hospital

2021 ◽  
Vol 31 (4) ◽  
pp. 5
Author(s):  
Niniek Budiarti Burhan ◽  
Herwindo Pudjo Brahmantyo ◽  
Djoko Heri Hermanto ◽  
Putu Moda Arsana
Keyword(s):  
Effective Treatment ◽  
Clinical Response ◽  
General Hospital ◽  
Female Patient ◽  
Critically Ill ◽  
Male Patient ◽  
Therapeutic Option ◽  
Descriptive Study ◽  
Plasma Therapy ◽  
Observational Descriptive Study

<p>The use of convalescent plasma has been beneficial for more than a century to treat various infections.  The lack of effective treatment currently available for COVID-19 has reemerged the use of convalescent plasma as a potential therapeutic option. This is an observational descriptive study in 13 COVID-19 patient who got convalescent Plasma. Consist of 11 (84%) male patient, 2 (16%) female patient. Divided into two groups based on severity, and outcome. 38% patient included in severe disesase and 62% patient in critically Ill condition. 30% patient who got convalescent plasma deceased, and 70% had a resolve condition.</p>

scholarly journals The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients

Medicina ◽  
2021 ◽  
Vol 57 (3) ◽  
pp. 257
Author(s):  
Livius Tirnea ◽  
Felix Bratosin ◽  
Iulia Vidican ◽  
Bianca Cerbu ◽  
Mirela Turaiche ◽  
...  
Keyword(s):  
Pilot Study ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Therapeutic Option ◽  
White Blood Cells ◽  
The United States ◽  
Plasma Therapy ◽  
Reactive Protein ◽  
United States Food ◽  
States Food

Background and Objectives: On 24 March 2020, the United States Food and Drug Administration (FDA) announced the approval of convalescent plasma therapy for critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emergency investigational new drug. This pilot study from Romania aimed to determine if convalescent plasma transfusion can be beneficial in the treatment of selected critically ill patients diagnosed with a SARS-CoV-2 infection. Materials and Methods: Donor and receiver eligibility for critically ill coronavirus disease 2019 (COVID-19) patients was based on Romanian guidelines issued at the time of the study. Here, we describe the evolution of a total of five eligible patients diagnosed with COVID-19 who received convalescent plasma (CP) in Romania. Results: In spite of our efforts and convalescent plasma administration, three of the five patients did not survive, while the other two recovered completely. Over the course of our five-day laboratory record, the surviving patients had significantly lower values for C-reactive protein, interleukin-6, and white blood cells. Conclusions: This pilot study provides insufficient evidence to determine the efficacy of convalescent plasma use as a therapeutic option for critically ill COVID-19 patients.

Nutrition-related outcomes and dietary intake in non–mechanically ventilated critically ill adult patients: A pilot observational descriptive study

2020 ◽  
Vol 33 (3) ◽  
pp. 300-308 ◽  
Author(s):  
Lee-anne Chapple ◽  
Michelle Gan ◽  
Rhea Louis ◽  
Alison Yaxley ◽  
Annabel Murphy ◽  
...  
Keyword(s):  
Dietary Intake ◽  
Critically Ill ◽  
Descriptive Study ◽  
Adult Patients ◽  
Mechanically Ventilated ◽  
Observational Descriptive Study

scholarly journals Epidemiology of Intra-Cerebral Hemorrhage in Young Adult Patients

2020 ◽  
Vol 11 (2) ◽  
pp. 65
Author(s):  
Melisa Melisa ◽  
Asra Al Fauzi ◽  
Anggraini Dwi Sensusiati
Keyword(s):  
Young Adults ◽  
Young Adult ◽  
Basal Ganglia ◽  
Intracerebral Hemorrhage ◽  
Ct Scan ◽  
General Hospital ◽  
Medical Records ◽  
Descriptive Study ◽  
Hematoma Volume ◽  
Observational Descriptive Study

Introduction: This study aimed to define the CT scan imaging of young adult intracerebral hemorrhage (ICH) patients in Dr. Soetomo General Hospital, Surabaya.Methods: This was an observational descriptive study. The data were collected retrospectively with medical records of 18 to 45 years old ICH patients who were treated in Dr. Soetomo General Hospital, Surabaya between 2014 and 2017. The collected data were then presented into tables.Results: 207 patients were identified in this study. The locations of the ICH were basal ganglia (45.89%), lobar (41.55%), thalamus (10.63%), brainstem (8.7%), cerebellum (4.83%), and others (3.86%). The volume of ICH varied from less than 30 cc (66.67%), 30 to 59 cc (27.54%), and more than 60 cc (5.8%).  Conclusion: The CT scan imaging of young adults ICH mainly had hematoma volume less than 30 cc and was mostly located in basal ganglia area then followed by lobar area. 

CLINICAL AND PARA-CLINICAL CHARACTERISTICS OF SICK NEWBORN BABIES TREATED AT PEDIATRIC DEPARTMENT OF HUE UNIVERSITY HOSPITAL

2011 ◽  
pp. 112-117
Author(s):  
Thi Kieu Nhi Nguyen
Keyword(s):  
Respiratory Distress ◽  
Congenital Malformation ◽  
Clinical Characteristics ◽  
Descriptive Study ◽  
Neonatal Unit ◽  
University Hospital ◽  
Pediatric Department ◽  
Sick Newborn ◽  
Observational Descriptive Study

Objectives: 1. Describe neonatal classification of WHO. 2. Identify some principal clinical and paraclinical signs of term, preterm, post term babies. Patients and method: an observational descriptive study of 233 newborns hospitalized in neonatal unit at Hue university‘ s hospital was done during 12 months from 01/01/2009 to 31/12/2009 for describing neonatal classification and identifying principal clinical and paraclinical signs. Results: Premature (16.74%); Term babies (45.5%); Post term (37.76%); Premature: asphyxia (43.59%), hypothermia (25.64%), vomit (30.77%), jaundice (61.54%), congenital malformation (17.95%); CRP > 10mg/l (53.85%); anemia Hb < 15g/dl (12.82%). Term babies: poor feeding (21.7%); fever (24.53%); CRP > 10mg/l (53.77%); Hyperleucocytes/ Leucopenia (35.85%). Post term: respiratory distress (34%); lethargy (29.55%); vomit (26.14%); polycuthemia (1.14%); hypoglycemia (22.73%). Conclusion: each of neonatal type classified by WHO presente different clinical and paraclinical. Signs. The purpose of this research is to help to treat neonatal pathology more effectively.

Clinical Characteristics and Convalescent Plasma Therapy in Severe and Critically Ill COVID-19 Patients

2020 ◽  
Author(s):  
Xiaowei Yang ◽  
Yi Sui ◽  
Fangfang Liu ◽  
Zhanfang Kang ◽  
Shangling Wu ◽  
...  
Keyword(s):  
Critically Ill ◽  
Clinical Characteristics ◽  
Plasma Therapy

scholarly journals Convalescent Plasma Therapy: An Effective Therapeutic Option to Treat COVID-19? A Narrative Review

2020 ◽  
Vol Volume 8 ◽  
pp. 7-21
Author(s):  
Ishita Ray ◽  
Diana Fiorela Sánchez ◽  
Chris Andrea Robert ◽  
Mary Phyllis Robert
Keyword(s):  
Therapeutic Option ◽  
Narrative Review ◽  
Plasma Therapy ◽  
Effective Therapeutic Option

Chemotherapy-sparing treatment of haemophagocytic lymphohistiocytosis with intravenous immunoglobulins and corticosteroids

2020 ◽  
Vol 13 (5) ◽  
pp. e234490
Author(s):  
Evan C Chen ◽  
Jonathan A Stefely ◽  
Bimalangshu R Dey ◽  
Walter H Dzik
Keyword(s):  
Effective Treatment ◽  
Disease Severity ◽  
Critically Ill ◽  
Intravenous Immunoglobulins ◽  
Current Treatment ◽  
Haemophagocytic Lymphohistiocytosis ◽  
Tailored Therapy ◽  
Fatal Disease ◽  
Therapeutic Challenge

Haemophagocytic lymphohistiocytosis (HLH) can be a rapidly fatal disease. Current treatment in adults is extrapolated from the HLH-2004 protocol that specifies a regimen of etoposide, dexamethasone and cyclosporine. However, HLH presents as a spectrum of disease severity. A therapeutic challenge arises for milder cases where the harms of potent chemotherapy such as etoposide may outweigh its benefit. We present a case of an adult with HLH who developed significant pancytopenia but was otherwise not critically ill and who responded to treatment with a chemotherapy-sparing approach consisting of intravenous immunoglobulins and corticosteroids alone. The case illustrates that tailored therapy may allow effective treatment of the disorder while minimising therapy-related toxicities.

Clinical characteristics and treatments of hereditary leiomyomatosis renal cell carcinoma: two case reports and literature review

2020 ◽  
Author(s):  
Dalin Feng ◽  
Mingshuai Wang ◽  
Xiaodong Zhang ◽  
Jianwen Wang
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Female Patient ◽  
Male Patient ◽  
Renal Cell ◽  
Clinical Characteristics ◽  
Genetic Test ◽  
Enhanced Ct ◽  
The Right ◽  
Hereditary Leiomyomatosis

Abstract Background The objective of this study is to discuss clinical characteristics and treatments of hereditary leiomyomatosis renal cell carcinoma on the basis of 2 cases and to review recent literature, in order to present medical advances. Methods A 29-year old male patient came to our hospital because of a huge tumour on the right kidney. Enhanced CT showed that the tumour was about 15.5*10.5 cm, and was considered to be malignant. Another case was a 38-year old female patient. She complained was found to have a right kidney tumour in a routine physical examination. Enhanced CT showed an early-stage tumour of about 4.3*3.7 cm on the lower pole of the right kidney. The male patient underwent open radical nephrectomy and the female patient underwent laparoscopic radical nephrectomy and extensive retroperitoneal lymph node dissection. The two patients underwent genetic testing and were diagnosed as having hereditary leiomyomatosis with renal cell carcinoma. Results The postoperative pathology in both patients revealed type 2 papillary renal cell carcinoma but with different prognosis. The male patient suffered multiple metastasis 10 months post-operation. The metastatic tumour of the abdominal wall was resected to confirm recurrence and hereditary leiomyomatosis renal cell carcinoma was diagnosed by the genetic test. While the female patient had a specific family history and uterine leiomyomas, the genetic test helped us to identify hereditary leiomyomatosis renal cell carcinoma pre-operation. Because of the early diagnosis and timely treatment, the female patient was considered to have a good prognosis. Conclusion Hereditary leiomyomatosis renal cell carcinoma is a rare hereditary disease resulting from FH gene mutation. There are currently no effective treatments.Our cases demonstrate that hereditary leiomyomatosis renal cell carcinoma is a very aggressive disease. Early screening and surveillance are recommended for patients with a family history or who are at risk of hereditary leiomyomatosis renal cell carcinoma. Surgical and palliative therapy still play an important role in clinical treatment.

Sign in / Sign up

Export Citation Format

Share Document